Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
5,554 people get AMGN articles and Market Currents by email alert.
Get email alerts on AMGN »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
PR Newswire (Thu, 4:18PM)
-
-
PR Newswire (Wed, 6:00PM)
-
-
-
-
-
-
-
PR Newswire (May 9, 2013)
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Why Amgen Still Has Valuation Upside RemainingValuentum • Fri, Feb 15 -
-
Is Amgen Running Out Of Steam In 2013?StockRiters • Tue, Jan 22 -
-
-
-
-
-
-
Amgen Management Discusses Q3 2012 Results - Earnings Call TranscriptTue, Oct 23, 2012
-
Amgen Management Discusses Q2 2012 Results - Earnings Call TranscriptThu, Jul 26, 2012
-
Amgen's CEO Discusses Q1 2012 Results - Earnings Call TranscriptTue, Apr 24, 2012
-
Amgen's CEO Discusses Q4 2011 Results - Earnings Call TranscriptThu, Jan 26, 2012
-
Amgen's CEO Discusses Q3 2011 Results - Earnings Call TranscriptMon, Oct 24, 2011
-
Amgen's CEO Discusses Q2 2011 Results - Earnings Call TranscriptFri, Jul 29, 2011
-
Amgen's CEO Discusses Q1 2011 Results - Earnings Call TranscriptWed, Apr 20, 2011
-
Amgen's CEO Discusses Q4 2010 Results - Earnings Call TranscriptTue, Jan 25, 2011
-
Amgen Management Discusses Q3 2010 Results - Earnings Call TranscriptTue, Oct 26, 2010
-
Amgen Q2 2010 Earnings Call TranscriptFri, Jul 30, 2010
-
Amgen Inc. Q1 2010 Earnings Call TranscriptThu, Apr 22, 2010
-
Amgen, Inc. Q4 2009 Earnings Call TranscriptMon, Jan 25, 2010
-
Amgen, Inc. Q3 2009 Earnings Call TranscriptWed, Oct 21, 2009
-
Amgen, Inc. Q2 2009 Earnings Call TranscriptTue, Jul 28, 2009
-
Amgen Inc., F1Q09Earnings Call TranscriptThu, Apr 23, 2009
-
at CNBC.com (Mon, 6:43PM)
-
PR Newswire (Thu, 4:18PM)
-
PR Newswire (Wed, 6:00PM)
-
PR Newswire (May 9, 2013)
-
at CNBC.com (May 1, 2013)
-
at CNBC.com (Apr 26, 2013)
-
at MarketWatch.com (Apr 26, 2013)
-
at CNBC.com (Apr 24, 2013)
-
at CNBC.com (Apr 24, 2013)
-
at MarketWatch.com (Apr 24, 2013)
-
at CNBC.com (Apr 24, 2013)
-
at CNBC.com (Apr 24, 2013)
-
at CNBC.com (Apr 23, 2013)
-
at CNBC.com (Apr 23, 2013)
-
at CNBC.com (Apr 23, 2013)
-
at MarketWatch.com (Apr 23, 2013)
AMGN vs. ETF Alternatives
Company Description
Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” and “us”) is the world’s largest independent biotechnology medicines company. We discover, develop, manufacture and market medicines for grievous illnesses. We focus solely on human therapeutics and... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Monday, January 23, 2012, 3:48 PM Part of J.P. Morgan's biotech (IBB -0.5%) cuts after the sector's recent run (I, II) include a move to Neutral from Overweight on Allos Therapeutics (ALTH +1.2%), noting that EU approval of its lymphoma drug looks at risk following last week's negative opinion from a European panel. Morgan's other calls lowered AMAG -6%, ACOR -0.5%, AMGN -2.5% and VPHM -2.4%. Comment! [Healthcare, On the Move]
- Monday, January 23, 2012, 9:53 AM Shares of AMAG Pharmaceuticals (AMG -4.4%) move lower after the firm takes on a downgrade from JPMorgan to Underweight. The ratings move on AMAG is part of a larger sector call that includes VPHM, ACOR, AMGN, and ALTH all getting slashed on valuation. Comment! [On the Move, Healthcare]
- Friday, January 6, 2012, 10:25 AM Lagging biotechs Amgen (AMGN -0.2%) and Celgene (CELG -2%) may dive into deal-making this year in seeking to return to the industry’s high-growth roots, Bloomberg speculates. Investors in the space have rewarded strategic acquisitions and companies that continue to develop innovative therapies, rather than dividend-paying low-growth stocks. Comment! [Healthcare, M&A]
- Thursday, December 29, 2011, 1:31 PM BofA weighs in on Amgen (AMGN +1.1%) after digesting recent events related to the firm including its planned buyback of $5B worth of stock. Analysts cite prescription sales trends and a favorable dollar/euro climate as drivers, as they slot in 2012 EPS at $6.13 vs. the Street's $5.82. Comment! [Healthcare, Quick Ideas]
- Monday, December 19, 2011, 4:36 PM Amgen (AMGN) and Watson Pharmaceuticals (WPI) will collaborate to develop and market several oncology antibody biosimilar medicines. Under the terms of the agreement, Amgen will assume primary responsibility for development and manufacturing, while Watson will contribute up to $400M in co-development costs, provide development support and will share product development risks. Comment! [Healthcare]
- Friday, December 16, 2011, 7:07 AM Goldman Sachs upgrades Amgen (AMGN) to Neutral from Sell on the heels of the biotech concern's change in management. Analysts with the firm have been calling for a "new strategic direction" for AMGN for quite a while. Comment! [Healthcare]
- Friday, December 16, 2011, 4:52 AM Amgen (AMGN) CEO Kevin Sharer will retire in May and be replaced by company President and COO Robert Bradway. RBC Capital analyst Michael Yee says the biotech's new CEO will need to "reinvigorate a focus of innovation for new products and a focus on cutting expenses." Are both those possible? (PR) 1 Comment [Healthcare, Top Stories]
- Thursday, December 15, 2011, 4:09 PM Amgen (AMGN) rises slightly after boosting its quarterly dividend by $0.08/share, to $0.36/share. Following the hike, Amgen sports an annual yield of 2.5%. Comment! [Healthcare]
- Tuesday, December 13, 2011, 7:01 PM Amgen (AMGN) says data from Phase 3 tests for its immune thrombocytopenia drug Nplate showed postitive results, and was presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology over the weekend in San Diego. Comment! [Healthcare]
- Thursday, December 8, 2011, 12:49 PM Biotech firm Amgen (AMGN) expects to repurchase almost $5B worth of stock - or around 83.3M shares at $60 a pop - following a Dutch auction. The buyback represents about half of a $10B program. Shares +0.4%. (PR) Comment! [Healthcare]
- Thursday, December 8, 2011, 11:33 AM Affymax (AFFY +41.3%) skyrockets following yesterday's recommendation by an FDA advisory panel for its peginesatide treatment of anemia in dialysis patients. Cowen believes the drug can capture $250M in U.S. sales by 2016, and Raymond James suspects AFFY can take market share if it prices its drug lower than Amgen's (AMGN +1%) Epogen. Comment! [Healthcare, On the Move]
- Wednesday, December 7, 2011, 6:14 PM Affymax (AFFY +8.9%) wins backing from an FDA advisory panel for its peginesatide anemia drug, which competes with a rival drug from Amgen (AMGN). AFFY shares jumped 20%-plus on Monday when briefing documents related to today's meeting were released; trading has been halted since early this afternoon. 1 Comment [Healthcare, On the Move]
- Tuesday, December 6, 2011, 1:16 PM Amgen (AMGN -0.2%) announces that it has struck an agreement with the FDA to modify its Nplate treatment designed to treat an immune system disorder that attacks blood elements. "The FDA has now concluded that enrollment in a restricted distribution program is no longer necessary to prescribe or receive Nplate." Comment! [Healthcare]
- Friday, November 18, 2011, 3:34 PM Dialysis clinic operator DaVita (DVA +3.1%) signs a new, seven-year agreement to receive Amgen's (AMGN -0.5%) anti-anemia drug Epogen. In an SEC filing, Amgen discloses that the Epogen it supplies will meet at least 90% of DaVita's requirements for erythropoiesis stimulating agents in clinics in the U.S. and Puerto Rico. Comment! [Healthcare, On the Move]
- Monday, November 14, 2011, 3:50 PM An experimental Amgen (AMGN -0.8%) drug shows it has the potential to lower bad cholesterol via an injected monoclonal antibody designed to inhibit the action of a protein called PCSK9, which is involved with the regulation of LDL (bad cholesterol). Sanofi (SNY) and Regeneron (REGN) are believed to have progressed the most in developing products that target PCSK9. Comment! [Healthcare]
- Tuesday, November 8, 2011, 4:12 PM Amgen (AMGN -0.7%) underperformed a little today after a U.S. appeals court gave a green light to a securities class-action lawsuit accusing the company of failing to disclose safety information for two anemia drugs, and of promoting unauthorized uses of its products. Comment! [Healthcare, On the Move]
-
- View all 0 replies
-
- View all 0 replies
-
The Scientist
CYTK: Wall St completely ignoring great results of ALS and HF drugs. AMGN should just buy them out. Ridiculously undervalued at $70M - View all 2 replies
-
The Scientist: Omecamtiv is a wonder drug that can be used in the ICU like water. It raises CO/SV; lowers BP/HR. Too good to be true.
-
briandiplacido: As a long-time ICU nurse who's seen tons of tachyarrythmia from inotropes, I agree (seems too good to be true). Interesting.
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
The Wall Street Transcript
Regulatory & Macro Clarity Stabilize Revenue, Earnings in Biotech; Analyst Discusses $ABT, $AMGN, $CELG, $GILD- http://su.pr/9MGqka - View all 0 replies
-
The Wall Street Transcript
Biotech Companies Develop Strong Pipelines & Outperform; Analyst Discusses $AMGN, $CELG, $GILD, $ONXX, $PFE, $SNY - http://su.pr/1s6jnX - View all 0 replies
-
- View all 3 replies
-
freefdawatchlist: don't buy more, because if fda delay it by 3 month, the stock may drop. Check out other stock which haven't rallied up till now.
-
-
The Scientist
CYTK has revolutionary heart medications. Multi-billion $ potential. Collaboration with biotech giant AMGN. - View all 0 replies
LATEST REPLIES